These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 37503523)

  • 1. The impact of expanded access to direct acting antivirals for Hepatitis C virus on patient outcomes in Canada.
    Chu C; Gomes T; Antoniou T; Wong WWL; Janjua N; Guertin JR; Schwartz KL; Feld J; Kwong J; Tadrous M
    PLoS One; 2023; 18(8):e0284914. PubMed ID: 37552677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of Hepatitis C over 28 years of monitoring Canadian blood donors: Insight into a low-risk undiagnosed population.
    O'Brien SF; Ehsani-Moghaddam B; Osmond L; Fan W; Goldman M; Drews SJ
    BMC Public Health; 2024 Aug; 24(1):2319. PubMed ID: 39192303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the COVID-19 pandemic on hepatitis C virus screening in provincial prisons in Montreal, Quebec, Canada.
    Kronfli N; Leone F; Dussault C; Miliani G; Gallant E; Potter M; Cox J
    Front Public Health; 2024; 12():1380126. PubMed ID: 39109158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding access to healthcare for people who use drugs and sex workers: hepatitis C elimination implications from a qualitative study of healthcare experiences in British Columbia, Canada.
    Cunningham NE; Lamb J; Staller A; Krajden M; Hogg RS; Towle A; Lima VD; Salters K
    Harm Reduct J; 2024 Apr; 21(1):75. PubMed ID: 38575970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equitable access to direct-acting antivirals: Canada's path to a hepatitis C-free tomorrow.
    Canani F; Feld JJ; Biondi MJ
    Can Liver J; 2024 Feb; 7(1):3-4. PubMed ID: 38505787
    [No Abstract]   [Full Text] [Related]  

  • 6. The Canadian hepatitis C treatment landscape: Time to turn chaos into order.
    Williams KP; Dunn KP; Lee SS
    Can Liver J; 2023 Jul; 6(2):187-189. PubMed ID: 37503522
    [No Abstract]   [Full Text] [Related]  

  • 7. The removal of DAA restrictions in Europe - One step closer to eliminating HCV as a major public health threat.
    Marshall AD; Pawlotsky JM; Lazarus JV; Aghemo A; Dore GJ; Grebely J
    J Hepatol; 2018 Nov; 69(5):1188-1196. PubMed ID: 29959953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study.
    Snell G; Marshall AD; van Gennip J; Bonn M; Butler-McPhee J; Cooper CL; Kronfli N; Williams S; Bruneau J; Feld JJ; Janjua NZ; Klein M; Cunningham N; Grebely J; Bartlett SR
    Can Liver J; 2023 Jul; 6(2):190-200. PubMed ID: 37503523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.
    Marshall AD; Saeed S; Barrett L; Cooper CL; Treloar C; Bruneau J; Feld JJ; Gallagher L; Klein MB; Krajden M; Shoukry NH; Taylor LE; Grebely J;
    CMAJ Open; 2016; 4(4):E605-E614. PubMed ID: 28018873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals.
    Nitulescu R; Young J; Saeed S; Cooper C; Cox J; Martel-Laferriere V; Hull M; Walmsley S; Tyndall M; Wong A; Klein MB;
    Int J Drug Policy; 2019 Mar; 65():41-49. PubMed ID: 30594080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variable access to antiviral treatment of chronic hepatitis B in Canada: a descriptive study.
    Congly SE; Brahmania M
    CMAJ Open; 2019; 7(1):E182-E189. PubMed ID: 30926602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing trends in direct-acting antivirals for the treatment of hepatitis C in Ontario, Canada.
    Tadrous M; Mason K; Dodd Z; Guyton M; Powis J; McCormack D; Gomes T
    Can Liver J; 2021; 4(1):51-58. PubMed ID: 35991476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be?
    Kronfli N; Buxton JA; Jennings L; Kouyoumdjian F; Wong A
    Can Liver J; 2019; 2(4):171-183. PubMed ID: 35992759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of practice and barriers to care for hepatitis C in the direct-acting antiviral (DAA) era: A national survey of Canadian infectious diseases physicians.
    Chan J; Young J; Cox J; Nitulescu R; Klein MB
    Can Liver J; 2018; 1(4):231-239. PubMed ID: 35992622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of public and private payments for direct-acting antivirals (DAAs) across Canada.
    Shakeri A; Hayes KN; Gomes T; Tadrous M
    Can Liver J; 2021; 4(4):426-429. PubMed ID: 35989895
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.